B2Broker Invests $5M in B2Trader - The Next-Gen Brokerage Platform
25.3.2024 21:15:00 EET | Business Wire | Press release
The crypto market is on an exciting growth journey, with Bitcoin hitting all-time highs and the total crypto market cap exceeding $2.37T. This coincides with the introduction of MiCA regulation, effective June 30, 2024, and followed by another wave on December 30, 2024, aiming to increase credibility and transparency, fostering wider crypto adoption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325324392/en/
B2Broker releases B2Trader, an industry-leading crypto spot brokerage solution. (Graphic: Business Wire)
With over 20,000 coins and tokens and a user base of over 300 million traders, compared to the FX market's 128 currency pairs and estimated 50 million traders, crypto is emerging as a more appealing trading option. Its expansion is fueled by its broad adaptation across finance, fintech, payments, and other sectors. Introducing innovative business models through technologies like L2 solutions and blockchain protocols.
To meet the booming crypto trading demand, brokerages are actively seeking solutions to enter the market. And in response, B2Broker announces the release of the B2Trader Brokerage Platform (BBP), a crypto spot broker solution designed to help businesses tap into this growing trend and start generating revenue faster than ever!
Who Can Benefit from B2Trader?
B2Trader is a powerful solution for crypto brokers (CFD and Derivatives), OTC brokers, FOREX brokers, multi-asset and multi-market brokers, market makers, liquidity providers, payment systems, and even banks to follow the market trends and enter the fastest-growing industry.
Here’s how each business model is able to utilise BBP:
FOREX Brokers
B2Trader can be an excellent addition to any FX broker. Along with the traditional trading platforms (MT4, MT5, cTrader, etc.) that mainly handle assets like FX, crypto, equity indices, and precious metals for margin trading or in the form of CFDs, you can add B2Trader to offer crypto spot trading exclusively, attract a new segment of crypto traders interested in physical delivery or ownership, and generate revenue through commissions, markups, and effective risk management.
Additionally, BBP offers a solution for regulated FX brokers to separate their digital asset trading under a different license, promoting strategic diversification and maintaining a competitive advantage in today’s market.
Crypto Brokers
Brokers focusing on crypto CFDs, using crypto as collateral, and offering a mix of FX and crypto CFDs can use B2Trader to enhance existing solutions with crypto spot trading.
Given the competitive nature of client retention and acquisition, the absence of crypto spot trading options could lead clients to seek services elsewhere. Thus, integrating B2Trader is a strategic advantage for brokerages, allowing them to adapt to market trends swiftly, offer much-demanded crypto spot trading, and meet client expectations.
Market Makers
Market makers can use B2Trader to access multiple exchanges, consolidate liquidity efficiently, achieve competitive spreads, optimise pricing, and enable smart routing execution across different venues.
Liquidity Providers
Adding cryptocurrencies to your asset offerings greatly boosts your appeal to brokers, hedge funds and professional traders. B2Trader streamlines this process, equipping you with the essential tools to expand your market reach and accelerate your earnings.
EMIs, Payment Systems, and Banks
For EMIs, PSPs, and banks, B2Trader provides a strategic edge by enabling diverse asset management, monitoring, and liquidity pool creation. It allows these entities to add crypto services to their existing operations, net all transactions, offer crypto accounts, and enable instant swaps.
BBP opens unlimited opportunities as your gateway to crypto and its booming trends. With its comprehensive API and a complete set of essential components and modules, B2Trader seamlessly integrates into any business model.
High-Speed, High-Efficiency, High-Tech
B2Trader is designed for the Enterprise scale of brokers to serve modern financial markets. Even in its most basic setup, it handles 3000 trading instruments and processes up to 3000 requests per second. It offers real-time market data, updates every 100 ms and ultra-fast order execution starting from 1 ms. This can be improved further by enhancing cloud resources and computing.
"Today, B2Broker is a leading name in the FinTech industry. We began operating in the FOREX industry in 2014 and have been developing solutions for the crypto industry since 2017. B2Broker has earned multiple awards and recognitions, and our years of experience have allowed us to understand what the market needs exactly.
That's why we created B2Trader. It's our answer to the changing trends in finance. We have poured 18 months of hard work and over $5 million into B2Trader. BBP is built by our dedicated in-house team of 40 engineers, each contributing to a solution that truly meets the demands of today's brokers. In the next 12 months, we are planning to double the team and enhance our offerings even further!"
— Arthur Azizov, CEO and Founder of B2Broker
Cutting-Edge Technology Stack
BBP focuses on reliability, scalability, and security, using the latest tools and protocols. It is hosted on AWS for its dependable infrastructure, reducing hardware risks. It utilises MongoDB and Amazon Redshift for data management and includes TradingView for market insights.
Kubernetes and Docker support scalable deployments, while CloudFlare provides DDoS protection. The FIX protocol boosts B2Trader's efficiency and reliability.
Powerful Integrations
Developed by B2Broker, B2Trader offers powerful integrations. B2Broker offers a comprehensive suite of products, including a trading platform, OMS, pre-trade and post-trade control, liquidity management system, Trading User Interface, CRM, back office, blockchain wallets for processing and collecting coins/tokens, blockchain management system for automatic payouts and settlements, mobile applications, technical documentation, REST and FIX API protocols, advanced White Label options, and much more.
Additionally, integrated with Marksman, a crypto liquidity distribution engine, B2Trader streamlines administration and ensures market updates with the latest data.
With Marksman, crypto brokers swiftly link to top exchanges by inputting API credentials after opening an account. This allows brokers to create diverse liquidity pools from various exchanges, assign specific execution and routing rules, and establish failover protocols for both the pairs and the liquidity pools.
B2Trader is available as a turnkey solution or for integration with any CRM via REST API. Contact the sales team or your account manager, try out the free demo, and launch your crypto spot broker within a week!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325324392/en/
Contact information
sales@b2broker.net
+44 208 068 8636
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom